Cellectar Biosciences
CLRB
9 hedge funds and large institutions have $961K invested in Cellectar Biosciences in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, reducing their positions, and 0 closing their positions.
172% more capital invested
Capital invested by funds: $353K → $961K (+$608K)
80% more funds holding
Funds holding: 5 → 9 (+4)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$586K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$266K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$184K |
| 4 |
Morgan Stanley
New York
|
+$54.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $395K | +$586K | +108 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $179K | +$266K | +49 | New |
|
|
VKH
3
Virtu KCG Holdings
New York
| $125K | +$184K | +34 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $85K | +$48.8K | +9 | +64% |
|
|
CAM
5
Cormorant Asset Management
Boston,
Massachusetts
| $65K | – | – | – |
|
|
6
Morgan Stanley
New York
| $59K | +$54.2K | +10 | +167% |
|
|
AS
7
Arxis Securities
New York
| $20K | +$27.1K | +5 | New |
|
|
AIC
8
AWM Investment Company
New York
| $19K | – | – | – |
|
|
AIM
9
Acrospire Investment Management
Chicago,
Illinois
| $10K | +$10.8K | +2 | +200% |
|
|
BFA
10
BlackRock Fund Advisors
San Francisco,
California
| $1K | – | – | – |
|
|
MFS
11
MSI Financial Services
Springfield,
Massachusetts
| $1K | – | – | – |
|
12
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
WAM
13
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $1K | – | – | – |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$2K | – | – |
|
CLRB Hedge Fund Activity: Q4 2016 in Review
9 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2016, worth a combined $961K — up 172% from $353K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLRB positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $586K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2K.
- 9 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2016, up from 5 in Q3 2016.
- Funds reported $961K of Cellectar Biosciences stock for Q4 2016, up 172% quarter-over-quarter.
- 4 funds opened new Cellectar Biosciences positions in Q4 2016 and 0 closed out, a net change of +4 holders.
- The largest Cellectar Biosciences buyer in Q4 2016 was Sabby Management, an estimated $586K added.
- The largest Cellectar Biosciences seller in Q4 2016 was Tower Research Capital (TRC), an estimated $2K sold.
Based on aggregated 13F filings for Q4 2016.